Apprentice.io, a Jersey City, N.J.-based intelligent software company for life science manufacturing that is helping to increase the speed to market on a number of COVID-19 vaccines, raised $24M in Series B funding.
The round, which brings Apprentice’s total capital to over $40M, was led by Insight Partners with participation from Pacific Western Bank, Pritzker Group Venture Capital, GFR Fund and The Venture Reality Fund.
The company intends to use the funds to continue to assist customers as they ramp up production.
Led by Angelo Stracquatanio, CEO & Co-Founder, Apprentice.io delivers a life science industry’s intelligent manufacturing execution system that helps teams scale faster – from COVID to cancer. From small and large molecule to cell and gene therapy, its cloud-based system leverages artificial intelligence, augmented reality and Pharma 4.0 to increase an organization’s speed to market. From batch execution to global collaboration, its end-to-end system helps manufacturing teams deliver lifesaving drugs to market faster.
The Apprentice System is a dynamic, end-to-end platform with a suite of intelligent software applications designed to streamline batch-based manufacturing and remote collaboration. Solutions include intelligent batch execution, augmented procedures/workflows, predictive resource management, event tracking, remote collaboration and immersive training.
The company supports Fortune 100 clients in life sciences and other complex, compliance-driven verticals across the U.S., Asia, South America, and Europe.